Target Discovery Program
Our Target Discovery Program aims at discovering and developing novel immuno-oncology antibody candidates, including novel immune checkpoint inhibitors. OREGA biotech integrates translational science insights to select the right immunology targets and advances programs that leverage contributions from its experienced academic founders as well as knowledge acquired from OREGA’s Target Discovery Platform to achieve rapid target validation and preclinical proof-of-concept.
Our Target Discovery Program already led to the recent discovery and validation of clinically-relevant targets for cancer immunotherapy. OREGA Biotech is pursuing efforts to discover novel immunoregulatory targets for cancer therapy through internal R&D, academic collaborations and industrial partnerships.